Table 3 HSV/VZV Treatment Recommendations for Neonatal/Pediatric Patients^{9,10}

Pathogen	Preferred Therapies and Duration	Alternative Therapies	Other Options/Issues
Herpes Simplex Virus (HSV)	Neonatal (birth-three months) HSV	HSV Infections During Acyclovir	- For pediatric (not neonatal)
	Infection	Shortage in Neonates:	patients, valacyclovir 20-25 mg/k
	Acyclovir 20mg/kg IV tid x 14-21 d	Ganciclovir 6mg/kg IV Q12h	PO tid has been shown to yield
	HSV Encephalitis (three months-	HSV Infections During Acyclovir	equivalent levels to Acyclovir 10
	12 year)	Shortage (Past Neonatal Stage)	mg/kg IV tid
	Acyclovir 20 mg/kg IV tid x 14-21 d	Ganciclovir 5mg/kg IV Q12h	- Valacyclovir oral solution can be
	HSV Encephalitis (12 years)	Acyclovir-Resistant HSV Infection	prepared by crushing valacyclov
	Acyclovir 10 mg/kg IV tid x 14-21 d	(Immunocompromised)	tablets in Ora-Sweet or Syrpalta
	HSV Infection in	Foscarnet 60 mg/kg IV bid	syrups to yield concentration of
	Immunocompromised Host	For VZV Patients Requiring IV	50 mg/ml.
	(Localized, Progressive, or	Therapy During Acyclovir	- Foscarnet monitoring: SCr, BUN
	Disseminated)	Shortage:	hypocalcemia, hypophosphatem
	< 12 years: Acyclovir 10 mg/kg IV	Neonate: Ganciclovir 6mg/kg IV	hypomagnesemia, hypokalemia
	tid x 7-14d	12h; preferred over Foscarnet 60	- Foscarnet infusion: administer a
	12 year: Acyclovir 5 mg/kg IV tid x	mg/kg IV bid	constant rate by infusion pump
	7-14d	Outside Neonatal Stage: Ganciclo-	(no faster than 1 mg/kg/minute)
	Herpes Zoster in Immunocompromised	vir 5 mg/kg IV Q12h; preferred	
	< 12 year: Acyclovir 20 mg/kg IV	over Foscarnet 60 mg/kg IV bid	
	tid x 7-10d		
	12 year: Acyclovir 10 mg/kg IV tid x		
	7d		
	Varicella in Immunocompromised		
	Host		
	< 1yr: Acyclovir 10 mg/kg IV		
	tid x 7-10d		
	1yr: Acyclovir 10mg/kg IV tid x 7-		
	10 d or 500mg/m2 IV tid x 7-10d		

RECOMMENDATIONS FOR HSV/VZV INFECTIONS IN IMMUNOCOMPETENT PEDIATRIC PATIENTS

- For skin recurrences following neonatal HSV disease (without CNS involvement at the time), 1st line therapy is oral acyclovir 20 mg/kg/dose (max per dose, 800 mg) PO QID. Second line therapy is oral Valacyclovir 20mg/kg/dose (max per dose, 1000 mg) PO TID.

- For HSV gingivostomatitis or HSV/VZV infection in an immunocompetent host, 1st line therapy is oral Valacyclovir 20mg/kg/dose (max per dose, 1000 mg) PO TID. Second-line therapy is oral Acyclovir 20 mg/kg/dose (max per dose, 800 mg) PO QID.

- For Zoster infection in an immunocompetent host, 1st line therapy is oral Valacyclovir 20mg/kg/dose (max per dose, 1000 mg) PO TID. Second-line therapy is oral Acyclovir 20 mg/kg/dose (max per dose, 800 mg) PO QID.